Healthcare, Pharma & Life Sciences

INTCO Medical H1 Revenue Jumps 40.6% as Glove Capacity Hits 107 Billion

ZIBO, China – September 03, 2026 -- INTCO Medical (300677.SZ) reported revenue of RMB 6.91 billion (approximately USD 1.03 billion) for the six months ended June 30, 2026, up 40.61% year-on-year, as the disposable glove maker expanded annual production capacity to 107 billion units.

Adjusted net profit surges 165% on operational gains

Net profit attributable to shareholders rose 17.86% to RMB 837.3 million (approximately USD 124.6 million). Adjusted net profit, which excludes one-off gains and losses, climbed 165.00% to RMB 1.06 billion (approximately USD 157.7 million), pointing to stronger underlying operating performance during the period.

Yale Secures $25M ARIA Grant to Map Developing Brain, Autism Origins

Image
Yale Secures $25M ARIA Grant to Map Developing Brain, Autism Origins

NEW HAVEN, Conn. -- Aug. 31, 2026 -- Yale School of Medicine has secured a nearly $25 million grant from the Aligning Research to Impact Autism (ARIA) initiative to build the first high-resolution map of the developing human brain and pinpoint where autism diverges from typical neural development.

The award, part of ARIA's Human Developmental Neurobiology Research Hub, funds two Yale-led projects within a four-project collaboration that also involves Harvard University. Combined, the initiative targets a gap researchers say has stalled autism drug and diagnostic development for decades: no detailed reference map exists for how the human brain wires itself in the first years of life.

Amgen's Repatha Cuts Death Risk 20% in High-Risk Heart Trial

Image
Amgen's Repatha Cuts Death Risk 20% in High-Risk Heart Trial

MUNICH, Germany -- September 02, 2026 -- Amgen's Repatha (evolocumab) reduced all-cause mortality by 20% in high-risk patients who had never suffered a heart attack or stroke, according to a pre-specified analysis of the Phase 3 VESALIUS-CV trial presented at the European Society of Cardiology Congress 2026 and published simultaneously in Circulation.

Trial data show mortality benefit emerging after 18 months of treatment
The analysis tracked more than 12,000 high-risk adults over a median of 4.6 years. Both overall deaths and cardiovascular deaths declined in the Repatha arm, with the survival curve separating at approximately 1.5 years and widening through follow-up. Amgen positions this as the first Phase 3 evidence that a PCSK9 inhibitor lowers all-cause mortality in a primary-prevention population.

Amgen's Repatha Cuts Death Risk 20% in High-Risk Prevention Trial

Image
Amgen's Repatha Cuts Death Risk 20% in High-Risk Prevention Trial

THOUSAND OAKS, Calif. -- September 01, 2026 -- Amgen said its cholesterol drug Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults who had not yet suffered a heart attack or stroke, based on a pre-specified analysis of the Phase 3 VESALIUS-CV trial. The company presented the data in a late-breaking session at the European Society of Cardiology Congress 2026 in Munich, Germany, and published the findings simultaneously in Circulation. Amgen said the result marks the first time a PCSK9 inhibitor has shown a reduction in all-cause mortality among primary prevention patients in a Phase 3 study.

Prasco Buys 130,000-Sq-Ft Carey, Ohio Facility to Expand Drug Distribution

Image
Prasco Buys 130,000-Sq-Ft Carey, Ohio Facility to Expand Drug Distribution

MASON, Ohio -- September 01, 2026 -- Prasco, LLC has acquired a 130,000-plus square foot distribution facility in Carey, Ohio, expanding the pharmaceutical commercialization company's automation, cold-chain and secure storage capacity beyond its existing Mason, Ohio operations. The deal, announced Aug. 31, 2026, adds a second Ohio campus for the company, which works with more than 65 brand partners and supplies medications to over 70,000 pharmacies nationwide. Prasco specializes in Authorized Generics and end-to-end commercialization services for global drug brands.

The Carey site sits inside what Prasco describes as the Midwest pharmaceutical and logistics corridor, giving the company direct highway access to CDMOs, national distribution centers and major health systems. Prasco said the location strengthens its footprint in Ohio, a state it identified as one of the most active life sciences markets in the country.

Opalescence Debuts Go Advanced Prefilled Whitening Trays, Cuts Packaging Waste

Image
Opalescence Debuts Go Advanced Prefilled Whitening Trays, Cuts Packaging Waste

South Jordan, Utah -- September 01, 2026 -- Opalescence Whitening launched Opalescence Go Advanced, a prefilled take-home whitening tray built on a redesigned UltraFit tray that eliminates the outer placement tray used in prior generations. The company, which markets itself as the top-selling professional teeth whitening brand worldwide, said the new product ships ready to use directly from the package. Opalescence has whitened more than 150 million smiles globally since its formula first reached the dental market 35 years ago.

Klinikum Frankfurt (Oder) Opens €6 Million Hybrid Operating Room

Image
Klinikum Frankfurt (Oder) Opens €6 Million Hybrid Operating Room

Frankfurt (Oder), Germany -- Klinikum Frankfurt (Oder) opened a new hybrid operating room on Aug. 31, 2026, backed by roughly 6 million euros in investment, RHÖN-KLINIKUM AG announced. The facility, one of five hospitals in the Rhön-Klinikum network, will serve as the primary site for vascular surgery and cardiology teams treating complex vascular and cardiac cases across eastern Brandenburg. Hospital managing director Christian Petersen and chief medical officer Prof. Richter-Ehrenstein presented the room as a step toward offering high-end interventional procedures rarely available outside specialized centers.

Veloxis Doses First Patient in Phase 2 Kidney Transplant Drug Trial

Image
Veloxis Doses First Patient in Phase 2 Kidney Transplant Drug Trial

CARY, N.C. -- September 01, 2026 -- Veloxis Pharmaceuticals dosed the first participant on Aug. 31, 2026, in its Phase 2 RENGEVITY-201 trial testing pegrizeprument, an investigational immunosuppressive drug, against tacrolimus in kidney transplant recipients. The Cary, North Carolina-based company, a unit of Asahi Kasei Corporation, will enroll up to 120 de novo kidney transplant patients across multiple sites in the randomized, partially blinded study registered as NCT07290777. Patients will receive one of two pegrizeprument doses or tacrolimus, each layered on top of rATG, corticosteroids and mycophenolate maintenance therapy.

Lilly to Pay Up to $2.875B for Merida Biosciences' Antibody Platform

Image
Lilly to Pay Up to $2.875B for Merida Biosciences' Antibody Platform

INDIANAPOLIS and CAMBRIDGE, Mass. -- Aug. 31, 2026 -- Eli Lilly and Company agreed to pay up to $2.875 billion in cash to acquire Merida Biosciences, a Cambridge, Massachusetts-based biotechnology company developing antibody-degrading therapies for autoimmune and allergic diseases. The figure includes an upfront payment plus contingent milestone payments under a definitive agreement announced by both companies. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.